Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucansartuzumab + tislelizumab as neoadjuvant therapy for resectable stage II–IIIB NSCLC
ChiCTR2600116747Phase 2Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lucansartuzumab and tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Shanghai Chest Hospital. Primary endpoint: Pathological Complete Response (pCR) Rate. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
lucansartuzumabtislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600116747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116747.